Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma

ASCO 2026

29 May - 2 Jun 2026

Published: 30 May 2026

Views: 15

Rating:

Save

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China

Dr Xue-Feng Leng reviews results from the phase III SCIENCE trial with ecancer at ASCO 2026, which showed that neoadjuvant chemoradiotherapy plus sintilimab improved pathological complete response rates in resectable locally advanced oesophageal squamous cell carcinoma.

The discussion also explores the potential of ctDNA clearance as an early biomarker of treatment response.

Related Videos

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

ctDNA predicts early treatment response in HPV-associated anal cancer

Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA

ctDNA predicts early treatment response in HPV-associated anal cancer ( Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA )

The potential of T-cell engagers in SCLC treatment

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

The potential of T-cell engagers in SCLC treatment ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

Tepotinib in second line NSCLC treatment

Dr Antonio Passaro and Prof Raffaele Califano

Tepotinib in second line NSCLC treatment ( Dr Antonio Passaro and Prof Raffaele Califano )

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL...

Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT ( Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA )

Choosing Wisely in endometrial & cervix cancers: Medical therapy

Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India

Choosing Wisely in endometrial & cervix cancers: Medical therapy ( Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India )

More from ecancer